National Pharmacovigilance Enquiry about Arixtra® (Fondaparinux)

Agnés Lillo‐Le Louët; Agnés Lillo‐Le Louët; David M. Smadja; David M. Smadja; Christine Le Beller; Christine Le Beller

doi:10.2165/00002018-200730100-00122

Related publications

Article2025

Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 years

Alexis Talbot, Alexis Talbot, Pierre-Édouard Debureaux, Pierre-Édouard Debureaux, Agnés Lillo‐Le Louët, Agnés Lillo‐Le Louët, Yasmine Derri, Yasmine Derri, Marine Aroux-Pavard, Marine Aroux-Pavard, Hélène Jantzem, Hélène Jantzem, David M. Smadja, David M. Smadja, Cyrille Touzeau, Cyrille Touzeau, Christine Le Beller, Christine Le Beller, Nicolas Gendron, Nicolas Gendron

Article2024

"Out and about": relationships between children's independent mobility and mental health in a national longitudinal study

Richard Larouche, Guy Faulkner, Mathieu Bélanger, Mariana Brussoni, Katie E. Gunnell, Mark S. Tremblay

Children s Geographies

Article1995

A Cautionary Note about the Cross-National and Clinical Validity of Cut-off Points for the Maslach Burnout Inventory

Wilmar Schaufeli, Dirk van Dierendonck

Psychological Reports

Article2003

Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery

Gordon Lowe, Peter Sandercock, Frits R. Rosendaal

The Lancet

Chapter in a book2012

PRINT®

Patrick M. Winter, Gregory M. Lanza, Samuel A. Wickline, Marc Madou, Chunlei Wang, Parag B. Deotare, Marko Lončar, Yoke Khin Yap, Jérôme Rose, Mélanie Auffan, Olivier Proux, Vincent Nivière, Jean‐Yves Bottero, Zhong Lin Wang, Ying Liu, R. G. Polcawich, J. S. Pulskamp, R. M. Proie, Woo-Tae Park, Sergei V. Kalinin, Brian J. Rodriguez, Andréi L. Kholkin, Gang Logan Liu, Jao van de Lagemaat, Lorenzo Valdevit, John W. Hutchinson,